4 results about "Titin Antibody" patented technology

The application discloses a water-in-oil-in-water adjuvant composition and a preparation method and application thereof, and belongs to the technical field of biological pharmacy. The adjuvant composition is composed of squalene, Tween-80, Span 85 and physiological saline or a phosphate buffer, wherein the volume percentage of squalene is 1% to 6%, the volume percentage of Tween-80 is 0.5% to 3%, the volume percentage of Span 85 is 0.5% to 3%, and the rest is solvent. The composition is prepared into uniform multiple emulsions with a particle size of 40 to 220 nm through high-speed shearing and high-pressure homogenization. The adjuvant can significantly enhance the humoral immune response of various vaccines, and the antibody titer is increased by 4 to 16 times compared with traditional aluminum adjuvant, meanwhile, the adjuvant has low local irritation and good safety, can be stored for more than 24 months at 2 to 8 DEG C, and is suitable for large-scale production.

The present application relates to the technical field of bio-chemical engineering, and particularly relates to a halogen-modified hapten for enhancing antibody affinity, and a preparation method and application thereof. The present application provides a halogen-modified sulfonamide hapten for enhancing antibody affinity, which is obtained by adopting halogen-modified sulfonamides, and the antibody prepared by the halogen-modified sulfonamide hapten has relatively high titer and affinity. The present application provides a new and effective approach for preparing high-affinity sulfonamide antibodies.

This invention discloses a chimeric peptide cFel d1-4 based on T-cell antigenic epitopes of feline allergen proteins Fel d1 and Fel d4, its encoding nucleic acid, and its applications, relating to the field of molecular biology. This invention provides a chimeric peptide cFel d1-4, comprising the region represented by amino acid residues 26-41, 46-59, 85-98, 132-140, and 146-153 of the feline allergen Fel d1 antigen, and the region represented by amino acid residues 1-12, 36-48, 83-94, 114-130, and 160-168 of Fel d4. Experiments of this invention demonstrate that the chimeric peptide cFel d1-4 immunizes animals and yields high antibody titers, simultaneously reducing the levels of both feline allergens Fel d1 and Fel d4 proteins.

The application discloses an influenza virus subunit vaccine and a preparation method thereof, and relates to the field of biological medicines. Each dose contains H1N1, H3N2 and Victoria; the influenza virus subunit vaccine is prepared through virus inoculation, proliferation culture, allantoic fluid harvesting, clarification, inactivation, ultrafiltration concentration, lysis purification, mixing, sterilization filtration and subpackaging. The application significantly enhances the dendritic cell targeted uptake and rapid release of antigens through the design of mannose modified small liposomes and pH responsive channels; in combination with the precise controlled release of the graded lysis micelles, the antibody titer and immunological persistence are obviously improved, the single dose protection period is longer, and the defects of the traditional trivalent vaccine in the insufficient immunological intensity are effectively made up.